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Introduction
A Brief Overview of Viruses
Viruses are non-living biological entities with enormous diversity that are able to
infect organisms from every kingdom of life. Viral infection in humans is the cause of
many well-known diseases, such as influenza and herpes. These viruses are notorious for
their detrimental effect on individuals and society. However, many viruses also serve a
wide variety of ecological roles, and can serve to benefit us in the biotechnology and
medical fields if we know how to utilize them properly.
Viruses are evolutionarily prepared to infect single cells of an organism and
utilize the cellular machinery to replicate. Viruses do not contain organelles of their own,
and rely on host cells for all of their protein production. The composition of a virus
includes a protein capsid encasing a nucleic acid genome, which may be ssDNA, dsDNA,
ssRNA, or dsRNA. Some viruses also have a phospholipid envelope. In order to hijack
the cell, viruses have developed different strategies of entry, some of which involve the
entry of a whole virus into the cell and others only injection of viral nucleic acid. Viruses
are then able to use various specialized molecular mechanisms to replicate their own
genome and produce necessary viral proteins in the cell. New viral progeny is assembled,
and released from the host cell, killing it.
Bacteriophages
Bacteriophages, or phages, are viruses that use bacterial cells as their hosts. They
were discovered independently by two individuals, the first of whom was Frederick W.
Twort. Twort recognized that a filterable agent was causing the death of bacterial cells on
plates. He did not use the term “virus” to characterize his observations, although at the
3

time filterable infectious agents of plants and animals were known. He wrote a paper in
1915 that is now regarded as the birth of modern bacteriophage research, but it was
disregarded for about five years after it was published. Frederick d’Herelle received
credit for the discovery of phages, after describing the lysis of bacteria in liquid medium
in 1917. D’Herelle was interested in the potential use of this bacteria-killing agent to
fight disease caused by bacteria, and his work following the discovery of phages was
focused on their biological properties, and their use as therapeutic agents. The pursuit of
phages as antimicrobials largely died out with the development of antibiotics in the
1930s.
Bacteriophages are the most common biological entities on the planet, with an
estimated population size of 1𝑥1031 individuals, outnumbering bacteria ten to one.
(Shors et al., 2013). Of all these phages, over ninety-six percent of them are tailed
phages with dsDNA belonging to the order Caudovirales, which use their tails as conduits
for genetic material being injected into their bacterial host (Ackerman et al., 2011).
Caudovirales can be separated into three families; Myoviridae, which have long,
contractile tails, and includes bacteriophage T4 and T4-like phages, among others. The
second family under the umbrella of Caudovirales is Podoviridae, which are
characterized by short, non-contractile tails, and include T7 and T7-like phages. The third
family is Siphoviridae, including bacteriophage lambda, which have long, non-contractile
tails, and are known for their distinct genetic code. Other phages are not tailed, falling
outside these three orders, and may be filamentous or polyhedral in morphology
(Ackerman et al., 2011). Bacteriophages, as such a large and diverse group, are hard to
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classify definitively. However, important features such as morphology and genetic
makeup can contribute to our understanding of their relationships to other bacteriophages.
Two types of lifecycles, lytic and lysogenic, have been described in the world of
viruses. Both involve specific viral molecular strategies for hijacking host cellular
machinery to support viral replication. Lytic phages immediately begin creating progeny
and kill host cells rapidly. Temperate or lysogenic phages may exist in a latent state,
incorporating their genome into the hosts, and existing there temporarily as a prophage.
These cells are free to live and divide, indirectly replicating the viral genome as they do.
Eventually, latent viruses reactivate and begin propagation effectively switching to a lytic
life cycle. Both types of lifecycles begin with a stage called adsorption, in which the virus
attaches to the host via receptors on the cell surface. Phages often accomplish this using
their tail fiber proteins to recognize these receptors. Next the viral genome is injected into
the host cell, and in the case of tailed phages, the genetic material travels down the
tubular structure into the cell. In lytic phages, biosynthesis would begin quickly, and the
phage utilizes the host’s resources to replicate its own genome and translate new proteins.
The new phages are assembled in the cell, and then are released back into the
environment.
Bacteriophages in general have a limited host range, known to successfully
infect few host species.

This property allows phages to be used in effectively in

identification of bacterial serotypes, or variations within bacterial species, which are
often hard to distinguish using conventional methods. The ability of a phage to infect and
lyse certain bacteria assists researchers in narrowing down the possible identities of an
unknown organism (Haq et al., 2012).
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Phages in the Environment
Bacteriophages are common in the environment, and can be found in many of the
expected locations of their hosts, and commonly in greater numbers. In oceans and
freshwater lakes, phages outnumber bacteria in a volume of water, and also have a greater
diversity (Chibani et al., 2004).
Marine bacteriophages are recognized as a critical component in bacterial carbon
recycling through the lysis of bacterial cells. Obtaining more information about how
these phages work will only contribute to our understanding of global ecology.
Synechococcus and Prochlorococcus are two examples of Cyanobacteria that are infected
by a type of phage known as Cyanophages. These two bacterial genera alone are
responsible for about half of the world’s primary production, making the phages that
infect them of interest at a large scale to determine their impact on global carbon cycling
(Clokie et al., 2011).
Bacteria are commonly found in the guts of animals, including mammals, and
often aid in digestion and contribute to an organism’s overall health. The ecosystem
found within an animal’s gut is commonly referred to as its gut microflora. Phages are
also known to be part of this gut microflora. However, quantitation of the bacteria in the
guts of these animals demonstrates higher concentrations of the prokaryotes than the
presence of phages normally allows. It has been suggested that the GI tract environment
might be prohibitive for phage adsorption, due to factors such as pH, nutrient availability,
relation to mucosa, and the possibility of the presences of phage inhibiting substances.
Bacteriophages are best studied in the microflora of non-ruminant mammals, and there is
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still a lot to be learned about their role in the gut ecology of other types of animals, such
as reptiles and amphibians (Letarove et al., 2009).
As with many known predator-pair relationships in nature, bacteriophages are
often considered a driving force in the evolution of their bacterial hosts. Phages can drive
bacterial evolution much as another predator might, by selecting for individuals that are
able to evade infection by phages (Breitburt et al., 2005) In addition, phages have the
ability to transfer genes from one bacterium to another, contributing to the genetic
diversity of a population of bacteria (Breitburt et al., 2005). Some phage genomes code
for virulence factors that can be transferred to bacterial genomes, and can change the
bacterial phenotype to a pathogenic one. For example, a pathogenic strain of E.coli,
O104:H4, gains its pathogenicity in the form of a gene that codes for Shiga toxin, which
is transferred from a phage genome (Turner et al., 2011). This is one reason careful
consideration is required when selecting phages to use as treatments or components of a
treatment in humans.
Bacteriophages in Biotechnology
Due, in part, to their molecular simplicity, phages can be manipulated for directed
use in various applications of modern biotechnology. Applications of phages discussed
herein include phages as anti-microbials, phage display, and utilization of phage-coded
enzymes for use in laboratory applications.
Phages as Anti-Microbials (Bacteriophage Therapy and Biocontrol)
Upon first recognition of bacteriophages as infectious agents of bacteria, it is a
natural inclination to attempt to use them for the lysis of pathogenic bacteria. Indeed,
these applications can be successful and were a focus of research when phages were first
7

recognized for their potential in the 1920s, but was largely abandoned when conclusions
about the efficacy of such treatments were variable, and antibiotics were developed in the
1930s (Shors et al., 2013). In modern medicine, antibiotic resistant strains of pathogenic
bacteria have begun cropping up, making new modes of attack necessary. This has turned
attention back to the potential of bacteriophages to combat bacteria.
One concern this strategy raises is whether it can be expected that infectious
bacteria will develop resistance to phage therapy, since bacteria have been shown to be
able to rapidly develop resistance to phages in laboratories. This occurs most commonly
via alterations of the bacterial extracellular receptors (Örmälä et al., 2013). The
development of resistance may not be as problematic as antibiotic resistance since
bacteriophages are a diverse and dynamic group, capable of change that could alter their
ability to infect bacteria, just like they do in nature.
Bacteriophages being used as an anti-microbial tool may have applications in
treating human diseases, but also show promise in food-safety and agricultural
applications. For instance Xanthomonas pruni is a bacteria known to cause spots on
peaches, and has been successfully controlled by phage-mediated biocontrol (Haq et al.,
2012). Phages have also been used to control Listeria contaminations in meats. Because
phages are so commonly present in the environment, these treatments are not required to
be listed by food manufacturers, as it is presumed phages would already be present in
significant quantities in the products in question (Hudson et al., 2009). It is likely that
these techniques will become more refined over the coming years, and possibly more
universally adopted.
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Phage Display
Phage display is a technique with a variety of applications. When a peptide
sequence is attached to a phage’s major capsid protein using molecular biology strategies,
hundreds of copies of the engineered protein can be displayed by a single phage. Phage
display techniques have been used to create combinational libraries that contain high
quantities of different phage clones displaying various encoded peptides on their capsids
(Samoylova et al., 2009). These phages can be sorted through to find polypeptides that
will have high affinity for target proteins through biopanning. The technique is
commonly used to identify contact surfaces between proteins and to select for high
affinity antibodies.
Another unique application of phage display is to label phages for studying the
processes and behavior of phages themselves. Having T4 phage display a fluorescent
protein (GFP) aided in the visualization of the phage and allows the study of its
interactions with living mammalian tissues and organs in the context of phage therapy.
(Kaźmierczak et al., 2014).
Phage Enzymes Commonly Used Nucleic Acid Manipulation
Enzymes that are commercially marketed for laboratory use are often products of
phage genomes. These enzymes can have properties not found in other forms of life that
make them more useful in specific applications and protocols. These enzymes are often
surprising in their versatility, as some can be used outside of the expected prokaryotic
applications.
DNA polymerases are often utilized in molecular biology techniques that require
the replication of DNA. One polymerase that is used from phages is T7 DNA
9

polymerase. The protein acts in two ways, both as a polymerase, and a 3’-5’ exonuclease
(Grippo et al., 1971). T7 DNA polymerase is ideal for making copies of long stretches of
DNA. The commercially available version of this enzyme is created using two
components, one is gp5 of T7 bacteriophage, the other is Thioredoxin from E. Coli.
Genetically engineered T7 DNA polymerase is known as sequenase and is used in
dideoxy sequencing.

Another phage-originating DNA polymerase used is T4 DNA

polymerase. It has the same two functions as the T7 version, and is regarded as the best
polymerase for use in creating blunt ends (Tabor et al., 1989).
When ligation is necessary in laboratory protocols, several phage-coded ligases
are commercially available, all with different specific properties. Ligase is used for
forming bonds in the sugar-phosphate backbone of nucleic acids (Figure 1). T4 DNA
ligase can be used to join blunt-end termini of DNA or RNA by catalyzing the formation
of a phosphodiester bond of a 5’ end and a 3’ end that are located next to each other. It
can also repair nicks in the backbone of double stranded molecules of DNA, RNA, or
DNA/RNA hybrids (Engler et al., 1982). Another phage ligase available is T3 DNA
ligase. T3 DNA ligase works with dsDNA. It serves a similar function to that of T4, but it
exhibits a higher tolerance for NaCl in a reaction (Cai, 2004). T7 ligase is also
commercially available for ligation of dsDNA, but it does not catalyze blunt-end ligation
efficiently. T4 RNA ligases are also available, and can be used for ligation of ssDNA or
ssRNA. Examples of applications for using these enzymes are making single-stranded
oligonucleotides or incorporating unnatural DNA sequences into genes (England et al.,
1977). The range of specifications available from phage enzymes is useful for obtaining
tools for procedures that have specific requirements.
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An example of a DNA degrading enzyme that is commercially available is T7
exonuclease, which is a product of bacteriophage T7 gene 6 (described in detail below).
This enzyme is able to degrade dsDNA starting at the 5’ end, or starting from nicks or
gaps. It can also degrade RNA and DNA in RNA/DNA hybrids, but cannot degrade
ssRNA or dsRNA.

Figure 1: DNA Ligation. Ligase catalyzes the formation of the bonds in sugarphosphate backbone of the DNA after the nitrogenous bases have formed Hydrogen
bonds with each other. This figure was originally published in Endy et al., 2007.
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CRE Recombinase from bacteriophage P1 is interesting in its ability to function in
eukaryotes, making it useful in creating recombinant animals, such as in transgenic mice,
to study gene function. CRE Recombinase catalyzes site-specific recombination at a 34
bp sequence called loxP. The result of CRE Recombinase on two strands of DNA that
each have a loxP site would be the fusing of these two DNA strands (Abremski et al.,
1984). Uses of phages in biotechnology are still in development, but specific strategies
here have been in the works for years or decades, and have demonstrated a degree of
success. Knowing that there is so much to be learned in the world of phages, it is logical
to expect that as science develops a clearer picture of phage biology that more
applications will emerge for use in the field.
T7 Bacteriophage
Bacteriophage T7 is a member of the order Caudovirales, which consists of tailed
bacteriophages, and the family Podoviridae, which is characterized by a short, noncontractile tail and a linear, double-stranded DNA genome (Ackerman et al., 2011)
(Figure 2). This phage infects E.coli in a lytic cycle, and is among the relatively few
well-studied phages in biology. This is partially due to the wide availability of its host
and the ability to culture it easily in a laboratory setting (Clokie et al., 2011). The tails of
Podoviridae bacteriophages vary from species to species, but have similarities that seem
to suggest a common mechanism for DNA delivery into the host cell. These similarities
include a tubular structure surrounded by fibers. The T7 tail is composed entirely from
the arrangement of four proteins, including connector protein (gene product 8, or gp8),
gatekeeper protein (gp11), nozzle protein (gp12), and a fiber protein (gp17) (Cuervo et.
12

al., 2011). Investigating these proteins can demonstrate T7’s relationship to other viruses,
and help establish functions for the individual proteins involved in T7, and the
homologous proteins found on other Podovirales phages. This phage, as one with a
wealth of information already known about it, provides the opportunity to ask much more
specific questions about the functions and mechanisms of its proteins. T7 has a complex
viral shape, and a dsDNA linear genome. The entire genome of T7 bacteriophage is
approximately 40,000 base pairs in length and codes for 55 proteins.

Figure 2: Illustration of a T7-Like Bacteriophage. Gene products that make up the tail,
inner core, and capsid are labeled and color-coded, as well as a whole outside illustrated
view. This figure was originally published by the Swiss Institute of Bioinformatics, 2009.

T7 Replisome and GP6
All of the proteins that work together to replicate DNA in one synchronized
machine are collectively known as a replisome. Although some of the T7 replisome
proteins are utilized by biotechnology, not all of the characteristics and interactions of the
specific proteins are fully understood. In vitro, only four T7 proteins are necessary to
13

replicate DNA. These proteins are gp5 (polymerase), gp2.5 (ssDNA binding protein), E.
coli encoded thioredoxin, and gp4, which functions as both a helicase and a primase,
(reviewed in Lee, et al., 2011 and Hamdan et al., 2009, Figure 3). The only protein in the
T7 replisome that is not encoded by the phage’s genome is the thioredoxin (trx), which
serves as a processivity factor for T7 polymerase, enabling it to stay associated with
primer-template for the addition of many more nucleotides before dissociation than gp5
by itself (Hamdan et al., 2009).
Gp2.5, or single stranded DNA binding protein, is an instrumental protein for the
replication process. It has a structure that allows it to coordinate replication proteins by
exposing its C-terminal tail when it is bound to ssDNA (Figure 4, Marintcheva et al.,
2008). This ability to coordinate proteins makes gp2.5 a key player in replication,
recombination, and DNA repair, and raises the question of how it is able to interact with
the other proteins.

Phage Encoded

Host Encoded

Gene

Function

Gene

Function

Gp 5

DNA polymerase

Trx A

Processivity Factor
of Gp 5

Gp 4

Helicase/Primase

Gp 2.5

ssDNA Binding
Protein

Figure 3: Necessary Proteins for T7 DNA Replication In Vitro.
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Figure 4: GP2.5 Function. The C-terminal tail of ssDNA binding protein is able to bind
to the positively charged cleft where ssDNA can bind. When the protein is bound to DNA,
the tail is freed to interact with other proteins. This figure was originally published in
Marintcheva, et al., 2007.
Because of the directionality of DNA synthesis, (DNA is synthesized 5’ to 3’),
replicating both anti-parallel strands of the double helix simultaneously results in a
lagging strand and a leading strand. The leading strand is able to be continually replicated
by polymerase, while the lagging strand must be replicated in short pieces as the template
is exposed by the helicase. These short pieces formed on the lagging strand are called
Okazaki fragments. Single-stranded DNA binding protein is essential for stabilizing the
lagging strand of DNA during replication, and in the T7 replisome, it has also been
implicated in organizing the other players in replication to be able to simultaneously
replicate both strands of DNA with the same machine. The lagging strand of DNA is
looped in order to come in contact with the replisome machinery (Figure 5). Gp2.5 is
known to directly interact with gp5 (DNA polymerase), and gp4 (helicase/primase)
(reviewed in Marintcheva et al., 2006). The specific interactions within the replisome are
not well understood. One approach used to learn more about the protein interactions, and
reveal physical sites of interaction, is a suppressor mutation screen.
Marintcheva et al. performed a suppressor mutation screen using mutations in the
C-terminal tail of gp2.5. The suppressor mutation screen was performed by introducing
gp2.5 lethal mutations into the phage genome and selecting for a viable phage. T7
15

carrying lethal gp2.5 mutation can become viable only if the mutation is suppressed or
reversed. These new compensatory mutations are called suppressor mutations, as they
suppress the lethal phenotype (Figure 6). Gp2.5 is an ideal candidate for performing such
a screen because it interacts with many other proteins to coordinate their functions. One
of these GP2.5 mutations that produced extragenic mutations swapped the positions of
amino acids aspartate, which is polar and hydrophilic, and phenylalanine, which is nonpolar and hydrophobic. Two point mutations in gp6, W42C and E120D, were shown to
suppress the lethal phenotype mutation with both mutations present on the gene
(Marintcheva et al., 2009).

Figure 5: The T7 Replisome. Gp2.5 is seen in pink, and plays a role in coordinating the
lagging strand with the replisome by stabilizing the ssDNA loop. Gp5, polymerase, is
shown in green, and helicase in red and blue. Figure originally published in Hamdan, et
al., 2009.
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Figure 6: Suppressor Mutation Molecular Mechanism. The suppressor mutation screen
revealed potential interactions between GP 2.5 and GP6, when two mutations in GP6
acted to suppress the lethal phenotype created by the GP2.5 mutation, so the phage was
viable, as it is with wild-type proteins.

T7 exonuclease, or gp6 of bacteriophage T7, is a commercially available DNA
degrading enzyme. This enzyme is able to degrade dsDNA starting at the 5’ end, or
starting from nicks or gaps. It can also degrade RNA and DNA in RNA/DNA hybrids,
but cannot degrade ssRNA or dsRNA. The enzyme, when functioning as an exonuclease,
enables the breakdown of the host genome for use in the assembly of the T7 genome.
Gp6 can also directly aid in rescuing stalled replication forks, enabling replication to
continue (Figure 7).
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Figure 7: Gp6 Functions. Gp6 is depicted in red, gp5 in green and gp2.5 in pink. The
figure displays two functions of GP6, as an exonuclease and a flap endonuclease. This
figure was originally published in Mitsunobu et al., 2015.
Research Goal
The two point mutations in gp6 described above (W42C and E120D) are what the
research herein is poised to investigate, by re-creating these mutations using PCR
strategies. In the first mutation, tryptophan (W) is replaced with cysteine (C) at the 42nd
position in the amino acid sequence. Tryptophan is a bulky and hydrophobic amino acid,
18

while cysteine is more compact, and hydrophilic. This mutation would therefore change
how the protein could interact with others, and likely the causative agent of the
suppressor phenotype. In the second mutation, glutamic acid (E) is replaced with aspartic
acid (D) at the 120th amino acid location. Both of these amino acids are hydrophilic and
charged, while glutamic acid has a slightly longer side chain. These amino acids would
interact with other proteins in a similar manner, and therefore this mutation is less likely
the causative mutation of the suppressor phenotype.
In order to determine definitively whether one of the two mutations or both are
necessary for the suppressor phenotype, three versions of the gene must first be
generated; a version with mutation W42C, a version with E120D, and a version with both
mutations. These mutated versions of gene 6 will ultimately be inserted into plasmids for
later use in complementation and suppressor assays. These assays will be used to
determine whether both gene 6 mutations must be present to suppress the lethal
phenotype induced by the mutation in gp2.5, or if either W42C or E120D can cause the
suppressor phenotype on its own.
These interactions are important to understand thoroughly because of the proteins’
applications in biotechnology, and also because the T7/E. coli relationship is a wellstudied phage host relationship, and can lay a foundation for information about how
phage replication proteins work. The groundwork laid by this research will ultimately
lead to a better understanding of how gp2.5 works, specifically in how it is capable of
coordinating activity at the replisome by interacting with gp6.

19

Materials and Methods
Generation and Evaluation of a New T7 Laboratory Stock
Soft Agar Plating
In soft agar plating, 0.5 ml bacterial culture and 3 ml melted soft agar and viral
stock are mixed and then poured on a plate with a hard agar base. Once poured, the soft
agar solidifies, allowing bacterial growth in a thin monolayer. Viral plaques are seen as
clear areas free of bacteria in a field that is otherwise milky with bacterial growth. When
multiple dilutions of viral stock are to be plated on the same plate, the viral dilutions are
dispensed in labeled locations on top of the solidified agar, instead of being part of the
soft agar mix.
Generation of a new T7 Phage Stock
Wild type T7 bacteriophage was a generous gift from Dr. Charles Richardson,
Harvard Medical School. In order to generate a new viral stock, it was first necessary to
perform plaque purification to ensure the final stock would be uniform, as started from a
single virus. Plaque purification was achieved by picking a single plaque from the soft
agar plate with the tip of a micropipette and rinsing the tip in media. The resulting
mixture was used to begin a serial dilution to 10−5 , and the dilutions were each plated.
Several dilutions were plated to ensure the isolation of single plaques. After three rounds
of purification, a single plaque was selected to be used in the generation of a new viral
stock.
A culture of E. coli strain C600 in LB media was infected with T7 phage to form
a new viral stock. One single plaque from the final round of plaque purification was
stabbed with a micropipette tip and rinsed in LB media. This resulting mixture was used
20

to infect an E. coli C600 culture that had light absorbance at 600nm between 0.1 and 0.2.
The infected culture was incubated at 37°C without agitation for half an hour so that the
phages would be able to attach to the bacterial cells and inject their genetic material.
Next, the culture was incubated at 37°C with shaking. Measurements of absorbance were
taken every half hour of the infected culture and the corresponding control bacterial
culture (treated exactly the same, but containing no virus) until the infected culture was
completely lysed as evidenced by absorbance readings close to zero.
Determining Phage Titer
Determination of the number of phages in the resulting viral stock was
accomplished by doing serial dilutions of the stock. The dilutions were all plated on a
separate section of a single plate and allowed to grow in the dark overnight at room
temperature. They were incubated in the dark in order to prevent unnecessary DNA
damage from exposure to UV light. After incubation, the plate was evaluated to
determine which dilution would be most likely to form single plaques when plated
individually, and in the evaluation of the original stock (Figure 8). Dilutions that were
determined likely to yield individual colonies were spread over an entire plate, to find a
plate with a number of plaques that fell in the statistically usable range of 20-200 plaques.
The dilution used was 10−5 , so to determine the number of phages in a volume of stock,
the number must first be multiplied by 105 . The number of plaques counted would be
used to determine the phage concentration using the following formula:
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Figure 8: Quantification of the Generated Viral Stock. Multiple dilutions on the same
plate (left) were utilized to determine which dilutions would yield single plaques if spread
over an entire plate (right). These plaques could then be counted to determine the viral
titer.
PCR Mutagenesis
Primer Design
Primers were designed for use in both introducing the specific point mutations in
GP6 as well as replicating the whole gene via PCR (Figure 9). Pairs of primers were
designed to introduce each of the two mutations. The mutagenic primers contained the
desired new sequence flanked by the base pairs complementing the wild type sequence,
so during PCR amplification the primers would introduce a different base pair where they
bound. The forward primer at the start of the gene begins with the sequence “CACC” so
that the resulting gene would contain the matching base pairs to be inserted into the
pENTR/D-TOPO plasmid later.
In PCR I, oligos in each reaction were used to amplify one of two parts of the
gene, as well as introduce the point mutation. For example, one of the PCR I reactions
that generated the tryptophan to cysteine mutation used the forward primer binding to the
beginning of the gene, and a reverse primer containing the desired mutation surrounded
22

by the appropriate sequence surrounding the 129th base pair where the mutation is
located. The second reaction used the forward primer for the location of the mutation, and
the reverse oligo for the end of the gene. This strategy results in two pieces of the gene
that have overlapping sequences where the desired mutation is positioned.
A PCR program was designed that accounted for the melting point of the primers
used. The PCR program included the following steps: an initial, one-time melting
temperature of 95°C for 5 minutes, and then a repeated cycling of a denature step at 95°C
for 15 seconds, an annealing temperature of 61.2°C for 30 seconds, and an extend step of
68°C for one minute. After this cycle repeated thirty times, the samples were stored at
4°C.The first PCR reactions (0.3 µM oligos 1 and 2, 1 µL template DNA, 1X reaction
mix buffer, 2.5 units/50 µL polymerase, and 40.5 µL distilled water) served to create the
mutations, using a total of four reactions, each of which had a total volume of 50 µL. The
second PCR reactions (0.3 µM oligos 1 and 2, 10 µL each templates 1 and 2, 1X reaction
mix buffer, 5 units/50µL polymerase, and 21µL distilled water) replicated the entire
gene, one reaction for each of the two mutations.
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Start Primer, Forward, Binds to nucleotides 1-38 of Gene 6
Oligo Sequence: 5’CACCATGGCACTTCTTGACCTTAAACAATTCTATGAGTTACG
Gene Sequence: 5’
ATGGCACTTCTTGACCTTAAACAATTCTATGAGTTACG

W C Oligo, Forward, Binds to nucleotides 122-144
Oligo Sequence: 5’ GAGTTTGATGCCTCTTGCGAGGAAGAGATTTG
Gene Sequence: 5’ GAGTTTGATGCCTCTTGGGAGGAAGAGATTTG
W C Oligo, Reverse, Binds to nucleotides 122-144
Oligo Sequence: 5’ CCAAATCTCTTCCTCGCAAGAGGCATCAAACTCAGC
Gene Sequence: 3’ GGTTTAGAGAAGGAGGGTTCTCCGTAGTTTGAGTCG
E D Oligo, Forward, Binds to nucleotides 346-378
Oligo Sequence: 5’ CTTGATGCTCTTTGACCGCGAAGAGTTCTATTGC
Gene Sequence: 5’ CTTGATGCTCTTTGAGCGCGAAGAGTTCTATTGC
E D Oligo, Reverse, Binds to nucleotides 346-378
Oligo Sequence: 5’ ATAGAACTCTTCGCGGTCAAAGAGAGCATCAAGG
Gene Sequence: 3’ TATCTTGAGAAGCGCGAGTTTCTCTCGTAGTTCC
Stop Primer, Reverse, binds to nucleotides 879-903
Oligo Sequence: 5’ CTACGGTCTCCACAGGTAAATCTCC
Gene Sequence: 3’ GATGCCAGAGGTGTCCATTTAGAGG
Figure 9: Primers Designed to Introduce Each of the Two Point Mutations. Differences
between the original gene and the oligo are highlighted. In the Start primer, the CACC
sequence is necessary to base pair with the overhang sequence in the vector. The
differences in the mutagenic oligos (W C and E D primers) are the point mutation
being introduced through the replication of the sequence with these oligos.

Gel Electrophoresis
One percent agarose gels were used to separate DNA fragments, both to evaluate
the success of the PCR reactions based on the resulting fragment sizes, and extract the
DNA fragments to be purified and used. Gels were run using 1X TBE buffer at 100
Volts, for roughly 45 minutes each, unless otherwise noted. DNA was visualized in the
gels with the use of 0.001mg/mL ethidium bromide in the agarose gel and a UV light
box.
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Gel Purification
QIAquick extraction kit (Qiagen) was used to extract the PCR fragments from
the agarose gels once they were determined to be of the correct length. Bands were cut
from the gel and then the buffers of the kit were used to dissolve and extract the gel
according to the manufacturer’s recommendations.
TOPO Cloning
Topoisomerase was utilized in TOPO cloning reactions that would insert gene 6
with the CACC overhang into the desired vector (Figure 10). Two cloning reactions using
different amounts of PCR product were performed for each mutation, in order to insert
the genes into pENTR/D-TOPO vector (Invitrogen). All four reactions were allowed to
incubate at room temperature for 30 minutes.

Figure 10: The Mechanism of Topoisomerase in the TOPO Cloning Reaction.
Topoisomerase is used to bind the created PCR product into the pENTR/D-TOPO vector,
which could be subsequently transformed into competent cells. Picture originally
published by Invitrogen.
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Transformation
Cloning reactions were transformed into OneShot Top 10 chemically competent
cells (Invitrogen) by incubating the cells with the cloning reaction product on ice for 15
minutes, heat shocking the cells for 30 seconds in a 42°C water bath, and immediately
returning to ice. 250 µL S.O.C. medium was added to each vial of cells, and these were
incubated with shaking at 37°C for one hour. The resulting cultures were plated in two
different volumes for each culture on kanamycin containing media. The kanamycin
ensured only cells that contained the plasmid would grow. Once colonies grew, they were
used directly to inoculate new bacterial culture.
Bacterial Culture Growth
A solution of five milliliters of LB media with 0.006mg/mL kanamycin was
inoculated with a single colony and incubated with shaking overnight at 37°C.
Plasmid Isolation and Gene Verification
A QIAprep Spin Miniprep Kit (Qiagen) was used according to the manufacturer’s
recommendations to isolate plasmids from the cells. Plasmids isolated from these cultures
served as a template for PCR, using the same program as previously described, to amplify
the inserted gene. These PCR products were run on a 1% agarose gel to ensure the
presence of a DNA fragment of the size we expected. Plasmids with verified insert were
sent for sequencing.
Sequence Analysis
Samples of each of each plasmid verified by PCR was sent to Eurofins Genomics
to be sequenced using the dideoxy approach. Once sequencing results were received,
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BLAST was run to compare the received sequences with the original gene 6 sequence.
This allowed the verification of the presence of the expected mutations, and also the
intact gene. Forward and reverse primers were used to verify viable copies of the gene.
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Results
T7 Viral Stock Generation and Quantification
Three rounds of plaque purification were performed and a single plaque selected
to infect bacterial cultures for the purpose of viral stock generation. The infection was
monitored with measurements of light absorbance (OD600, directly monitoring the
density of the bacterial culture). For the first generation of stock, an initial absorbance of
0.13 was upon initial infection. The measurements of light absorbance gradually
increased as bacteria were dividing and reached a plateau when the rates of cellular
division and lysis reached equilibrium. As the rate of cell lysis increased due to the
progression of the infection, the optical density declined. The uninfected control
measured at the same time points showed a steady increase in absorbance as bacteria
replicated unimpeded by the virus, resulting in higher readings. Once the absorbance on
the infected sample read close to zero, it was assumed all bacteria were lysed and the
infection was complete, leaving the phage suspended in media. The second generation of
culture was treated the same as the first, with at an initial absorbance of 0.076.
The first infection, or generation I, was performed in a volume of 10mL. This
generation was used to infect a 50mL generation 2, using the same absorbance
measurements to observe the progress of the infection. To ensure generation 2 would be a
viable laboratory stock, the density of this new suspension needed to be determined. To
do this, serial dilutions of the stock to 10−11 were made and 5μL of each dilution was
plated in its own section on one of two plates.
When it was determined a third generation would be necessary to further increase
the density of the stock, a higher concentrated bacterial stock was used (about 0.2
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absorbance) and the viral stock was diluted to 1:10, its original strength. These alterations
were made to try to reduce the rate of viral infection, and allow for more rounds of
replication resulting in higher viral count. This generation was incubated, shaken, and
monitored as the previous two. The quantitation plates showed that we would likely get
single plaques by plating dilutions 10−5 and 10−6 which were plated separately to
determine the density of the new stock.
Once the third generation stock dilution 10−5 was plated by itself, it had 37
single plaques, which is in the ideal range for use in calculations. This number was used
in the formula in Material and Methods, leading to the final figure of
7.4 ∗ 108 viruses/mL. Overall, the produced phage stock was at the lower range for a
good viral stock, but with a usable concentration.
PCR Introducing Mutations
Primers were designed to incorporate two different point mutations into GP6 at
129 base pairs (bps) and 363 bps. These mutagenic primers are represented by the green
and blue arrows that overlap the mutation site. The primers on the ends of the gene can
also be used to later amplify the whole gene (Figure 11). In order to introduce the
tryptophan (W) to cysteine (C) mutation, W42C, at the 129th base pair, the gene was split
into pieces two pieces via PCR I of sizes 144 base pairs and 792 base pairs. The PCR I
fragments to create the glutamate (E) to aspartate (D) mutation, E120D, are 558 and 378
nucleotides in length. These fragment sizes were verified by a gel (Figure 12) PCR II was
designed to reassemble gene 6 from the overlapping fragments, to result in products that
are the full size of the gene, 903 base pairs. The PCR products from PCR 1 were gel
purified and used as templates to reconstitute the entire gene in PCR II amplification. In
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order to introduce the second mutation in one plasmid, the same two PCR procedures
were used, using the genes created with single mutations as the template.

Figure 11: PCR Strategy for Introducing Point Mutations. In this figure, blue arrows
follow the amplification of one gene fragment while green arrows follow the
amplification of the other gene fragment. These two pieces each contain the mutation,
and when they are reassembled in PCR II, the amplified gene contains the desired
mutation.
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Figure 12: Gel electrophoresis of PCR 1 and 2 Products. Lanes 2 and 3 of PCR 1 show
the W to C mutation products, 144 base pair length in lane 2 and 792 in lane 3. Lanes 4
and 5 in PCR 1 have the second mutation, for E to D. Lane 4 is 558 base pairs and lane 5
is 378. These fragments are reassembled into the whole gene in PCR 2. The gel for PCR
2 shows the successful reassembly of gene 6 in lanes 6 and 7. The gene is 903 base pairs
long. Lane 8 is the positive control at 130 base pairs. New England Biolabs’ Quick-Load
2-Log DNA Ladder was used.

Cloning of gp6 Variants Containing Single Mutations
After gene 6 was amplified in PCR with the desired mutations, the gene was
inserted into the pENTR/D-TOPO vector (Invitrogen) using an array of concentrations of
PCR product so that the optimal fragment to plasmid ratio could be found to yield the
best results (Figures 13 and 14). These reactions were transformed in to OneShot Top 10
chemically competent cells (Invitrogen) yielding cells containing the plasmid with the
kanamycin resistance gene.
Isolation of Transformed E.coli
After undergoing transformation, the cell cultures were plated on kanamycincontaining media to select for cells that had the plasmid. This step ensured that the cells
grown would all contain the plasmid, which contains the kanamycin resistant gene.
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Colonies were counted on the plates to be able to verify the number of colonies would be
congruent with the volume of culture plated. For all reactions with one mutation, viable
colonies grew, meaning all cloning reactions resulted in the uptake of plasmids (Figure
12) These colonies were used to inoculate culture to be used for the isolation of plasmids
containing the single mutations. These plasmids were tested for the desired insert via
PCR using primers to amplify gene 6 before they were sent for sequencing.
For the reactions that used the gene containing two mutations, overall fewer
colonies grew, but some colonies grew for every reaction (Figure 13). The growth of
colonies indicated successful cloning as well as successful transformation. These colonies
were used to inoculate new cultures from which plasmids containing both mutations
would be isolated, used as a template in PCR to verify the gene insert, and sent for
sequencing.
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PCR Product

TOPO Vector

Number of
Colonies
(50µL)

Number of
Colonies
(200 µL)

Tube 1
(W C)

0.5 µL

1 µL

32

101

Tube 2
(E D)

4 µL

1 µL

40

84

Tube 3
(W C)

1 µL

1 µL

34

101

Tube 4
(E D)

3 µL

1 µL

22

54

Figure 13: TOPO Cloning Reaction and Resulting Colonies for the Introduction of a
Single Mutation. Each of the four reactions were set up with different quantities of PCR
product and water, so that in the case one ratio did not work, an optimal reaction would
be easier to find, saving time if troubleshooting were necessary. This table also shows
how many colonies were counted on each plate resulting from the spread of transformed
E. coli onto selective plates, verifying the successful transformation of pENTR/D-TOPO
plasmid into the competent cells.
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Cloning
Reaction

PCR
Product

TOPO
Vector

Number of
Colonies (50µL)

Number of
Colonies (200 µL)

Tube 1a

0.5 µL

1 µL

9

65

Tube 1b

4 µL

1 µL

22

64

Tube 2a

1 µL

1 µL

5

29

Tube 2b

3 µL

1 µL

0

15

Control

N/A

N/A

0

0

Figure 14: Composition of Reactions and Resulting Colonies from Transformation of
Plasmids Containing gene 6 with Two Mutations. Each plate was counted for colonies
that contained the plasmid, as a way to verify the efficacy of the transformation process
and evaluate cells for plasmid content and gp6 content (achieved through plasmid
isolation and PCR amplification of gene 6 using previously designed primers.) The
control used in this experiment showed no growth on the kanamycin plates, but this was
due to an error in procedure. The control plasmid was resistant to ampicillin rather than
kanamycin, and displayed growth on the appropriate plate.
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PCR Determining the Presence of Gene 6 in Isolated Plasmids
A PCR verification step was utilized to demonstrate the insertion of T7 gene 6 in
the pENTR/D-TOPO plasmid. The PCR products for the first round of reactions for
which the plasmids each contained the gene with one of two mutations had uniform band
patterns which verified the presence of the gene, but also had much larger DNA present
which was not identified (Figure 15). These unexpected bands created some concern for
the quality of the plasmids, but it was decided to send the plasmids for sequencing.
Because the results were uniform, two samples of each mutation were chosen arbitrarily
for sequencing.
The PCR verification for the insert of the gene with two mutations was less
uniform, with isolations 1, 4, 5, 6, 7, 9 and 10 all with large DNA fragments present.
Samples 2, 3, and 8 showed clearly the presence of the gene without other DNA, so these
samples were chosen for sequencing. 1, 4, 9, and 10 were also sent for sequencing,
because they each had the correct fragment size for gene 6 in the gel. Samples 5, 6, and 7
were not sequenced because all bands present in the gel were too large to be gene 6
(Figure 16).
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Figure 15: Gel Electrophoresis to Visualize Gene 6 in Isolated Plasmids. This gel
shows the PCR results to amplify gene 6 in the isolated plasmids. Plasmids from all six
inoculated cultures were isolated. Lanes 1-3 contain the PCR products from the W to C
cultures, and lanes 4-6 contain the PCR products from the E to D cultures. All six show a
bright band where we expect the gene to appear, at around 1000 base pairs. New
England Biolabs’ Quick-Load 2-Log DNA Ladder was used.

Figure 16: PCR Verification of Gene 6 Insert in Plasmid for Gene Containing Double
Mutations. Lanes 2, 3, and 8 represent samples that were easily selected for sequencing
based on the clear results, showing a gene-sized fragment without noise. New England
Biolabs’ Quick-Load 2-Log DNA Ladder was used.
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Sequence Analysis
The Basic Local Alignment Search Tool, or BLAST, can be used to find similar
sequences of DNA, and align them based on similarity. This tool was used to compare
the wild type T7 gene 6 with the sequenced gene. In BLAST sequence alignment, lines
tying two bases together signify that they are the same. No line appears when the two
bases are different. These notations helped find any issues with the sequenced gene, and
helped identify the expected mutations where they ought to be. Any issues in the
sequenced DNA identified using BLAST could be examined in the chromatogram for the
corresponding sequence to determine if there was a problem with the gene.
Analysis of the sequenced DNA using BLAST led to the conclusion that the
samples labeled W1 and D1 both had the entire gene intact, included start codons and
stop codons, each with one of the two expected mutations Sample W1 contains the W42C
mutation (Figure 17). Sample D1contains the expected E120D mutation (Figure 18).
Because these two samples each have of one of the two desired point mutations, they
would be viable for use in future assays.
Plasmids that were expected to contain both of the mutations were also
sequenced, and then used in BLAST. Of the seven sequences received, only those labeled
4 and 10 had enough continuous sequence to see the whole gene. Of these, only 10 had
an entire intact gene, with the start codon and stop codon, and also contained both of the
expected mutations (Figure 19). This sample will be viable for use in future assays that
require a version of the gene that has both mutations.
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Figure 17: BLAST Results for Sample W1 and Selected Chromatogram W1
Chromatogram Segment. This sequence analysis shows the known gene 6 sequence
(Query) compared directly with the gene 6 sequence in the isolated plasmid of sample
W1. The start codon is highlighted in red, and the stop codon in yellow. The mutation at
base pair 129 is highlighted in light blue, this is the expected mutation that will change
the codon from coding tryptophan to cysteine. The green highlighted portions are
inconclusive sequence fragments from the reverse sequence that were successfully
verified using the sequence resulting from the forward primer. The chromatogram
segment shows the actual sequence results for the section of gene 6 that had the expected
W C mutation.
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Figure 18: Sample D1 BLAST Results and Selected D1 Chromatogram Segment. This
alignment shows the known sequence of gene 6 (Query) against the sequence from the
plasmid sample D1 (Sbjct). This figure shows the start codon highlighted in red, and the
stop codon in yellow. The mutation at base pair 363 that will cause the codon to code for
aspartate instead of glutamate is highlighted in light blue. This chromatogram segment
successfully shows the codon that will now encode for aspartate, in other words, the
expected E D mutation.
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A)

B)

Figure 19: BLAST Analysis of Double Mutation and Select Chromatogram Segments
from Sample 10. The Start codon is highlighted in red, the two expected mutations are
highlighted in light blue, the stop codon is in yellow, and a mismatched “N” highlighted
in green. In the chromatogram segments, A) shows the expected W C mutation and B)
Shows the expected E D mutation. Chromatogram results were also used to verify the
correct base is present where there is an “N” at location 278 on the subject (data not
shown).
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Discussion
The overall goal of this research was to create and verify plasmids that have three
versions of T7 gene 6. Two of these versions should each have one point mutation, and
the third should contain both of the other mutations. Throughout the creation of these
plasmids, steps have been taken to ensure the procedures were successful. Gels were run
to verify DNA fragment sizes after PCR I and PCR II, and to verify the amplification of
the gene after transformation. Kanamycin plates were used to verify the successful
transformation of the plasmids into competent cells. Finally, sequencing of isolated
plasmids was analyzed to ensure the mutations were in place and the rest of gene 6 was
intact.
PCR Introducing Mutations
The DNA fragments for PCR I and PCR II were verified only by evaluating their
size with gel electrophoresis. This enabled the verification that the primers were likely
binding at the intended sites, and that the PCR program was producing an appropriate
product (Figure 12). Bands could be evaluated qualitatively for yield, by the brightness of
the resulting bands. Because bands other than the expected gene fragments appear in gels
for PCR I and PCR II for inserting a single mutation, it is known that other DNA is
amplified by the PCR program. In PCR I, The whole T7 phage genome was used as a
template, so the extra bands of DNA, all of which are larger than the gene fragments,
could have been amplified from anywhere in the genome. PCR II was determined to be
successful with the verification that both PCR products (with different mutations)
resulted in the same sized DNA fragment that was the size of gene 6.
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When introducing the second mutation onto the gene, the template used was the
PCR amplified gene 6 with one mutation from the insert verification step. Using this as a
template, the resulting gels were surprisingly noisy, but both PCR I and PCR II for these
steps yielded the desired fragment sizes, among the others. One possible explanation for
larger DNA fragments to appear would be the annealing and extension of primers to
themselves. This does not usually take place when a template is available, but there
should not have been much large DNA for PCR to amplify, because the template used
had been isolated from agarose at the 1000 base pair mark.
Cloning Reactions and Transformation
The success of the cloning reactions and transformation was measured by the
formation of colonies on kanamycin containing media. In the first round (inserting the
genes that had one version of the mutation each), one plate with 50 µL and one plate with
200 µL of each of the transformations was made and incubated. It was expected that the
number colonies grown would reflect the 1:4 ratio of the volumes plated. After the
colonies were counted, however, the actual ratios were as follows: Tube 1 was ~1:3,
Tube 2 was ~1:2, Tube 3 was ~1:2, and Tube 4 was ~1:2.5. All reactions yielded some
colonies that could be utilized to create a culture.
The second round of transformation was done with plasmids containing gene 6
with both mutations. Each of the four vials of transformed competent cells were split into
50 µL and 200 µL volumes, plated, and incubated. Because of the 1:4 ratio of the
volumes plated, a similar ratio was expected for the numbers of colonies that grew on the
plates. The ratios observed were ~1:7 for Tube 1a, ~1:3 for Tube 1b, and ~1:6 for Tube
2a. The 50 µL plate for Tube 2b yielded no colonies, with 15 colonies on the 200 µL
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plate. All reactions in round 2 yielded colonies for use in inoculating a culture, however,
the second round yielded overall fewer colonies than the first round.
The difference in number of colonies between the first and second rounds of
transformation could have been a result of several factors, but it is likely in any case that
more competent cells took up plasmids in the first round, or that more genes were
successfully inserted into plasmids in this round. Successful gene insertion may have
been a function of the ideal ratios of the components of the cloning reaction. Therefore, if
the PCR yield used in the reactions had a vastly different concentration from round one to
round two, this could explain the difference in success. The final count of viable colonies
did not impact the ultimate goal of collecting colonies to culture for plasmid purification,
however, because some colonies grew for all reactions of each round, and only one
colony was needed to begin a culture.
Gene Insert Verification
Before selecting plasmid samples to be sent out for sequencing, a PCR was run
with the primers designed to amplify gene 6, using plasmids isolated from all six cultures
with single mutations as templates. For the single mutation gene amplification, the gene
was determined to be present in all samples. However, there were also very large DNA
fragments (with high molecular weight), uniformly seen in all 6 lanes. These were
determined to likely be the plasmid template, of which there was too much present.
The same amplification step was performed for all ten plasmid samples of the
gene containing the double mutation. This gel was less uniform, but large pieces of DNA
were also seen in some lanes. Lanes that only had gene 6 sized fragments (about 1000
base pairs), without any other noise, were considered ideal for sequencing. Samples were
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sent for sequencing from other lanes only if they had strong evidence for the presence of
the gene. Large DNA fragments appearing in this gel may also have been plasmids,
present in too high a concentration. This amplification step is critical for maximizing the
possibility of getting sequencing results with the desired insert, rather than wasting
resources sequencing all samples, or randomly selecting samples for sequencing that may
not contain the gene.
Sequencing Results
For the introduction of single mutations to the gene, plasmids were isolated for
sequencing from two cultures for each of the two expected mutations, for a total of 4
sequences. These sequences were high-quality and allowed the determination that one
sample of each desired mutation contained an intact gene with the mutation in the correct
locus.
Seven sequences were received for the verification of the double mutation in gene
6. These sequences were of a much lower quality, and most did not contain enough full
sequence to determine if the gene was intact, and the necessary mutations were present.
These low quality results had many nucleotides that were unidentified, “N” or not
sequenced at all. According to the sequencing party, Eurofins Genomics, possible reasons
for this outcome include the DNA concentration being too low for sequencing, or the
presence of contaminants such as buffer salts. The two samples that the whole gene was
visible in were 4 and 10. In the BLAST of sample 4 compared with the wild-type gene 6,
it was revealed that there were many mistakes in the gene, rendering it useless for the
intended purposes. Sample 10, however, was determined to have a start and stop codon,
both of the intended mutations at the correct loci, and all other base pairs were correct.
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Plasmid sample 10 is therefore viable for later use in assays investigating the double
mutation. With the information available, there is no way of determining if the other five
samples that were sequenced have all the characteristics desired for future assays.
Future Directions and Conclusion
The confirmation of gp6 with the expected mutations was the most significant end
result of this work. Moving forward, these plasmids can be used in complementation
assays to ensure the gp6 is viable, and suppressor assays to determine its interactions with
gp2.5. Complementation assays can be accomplished through infecting of E.coli
containing plasmids with one version of mutated gp6, and using T7 that is missing gene
6. If the gp6 in the plasmids is viable with the other wild-type replisome proteins of T7,
the phage will be able to replicate and form plaques.
Similarly, suppressor assays can be done by testing viability of the phage with
the mutant gp2.5 and the mutant versions of gp6. This could be accomplished using E.
coli that have a plasmid with the mutant gene 2.5, and one version of the mutant gene 6.
These cells would be infected with T7 phages missing gene 2.5 and gene 6. If the phage
was viable and able to replicate, then the gene 6 version used will sufficiently suppress
the lethal mutant gp2.5 phenotype. Each of the three gp6 versions would be used
separately, to determine if one of the two mutations was necessary, or both are necessary
to suppress the lethal phenotype. The results of these assays will give insight to how and
where these two proteins interact with each other. Based on the difference in chemical
properties of the amino acids in the W42C mutation, it is predicted that it is the change
that causes the suppressor phenotype. The chemical properties of the two mutations in
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E120D are less different, and therefore less likely to be causing a change in how gp6
interacts with gp2.5.
Bacteriophage T7 gp6 has potential for applications in biotechnology, and is
already available for purchase and use. This makes it all the more important to
understand how the protein normally works, and its interactions with other proteins, to
enable us to provide the best conditions for the protein to function as it is needed to in
biotechnology applications.
Even for the best-characterized groups of phages, we have plenty to learn about
their specific molecular mechanisms. Modern developments have shown great strides in
what we know about phages in their natural roles in the environment as well as shown
promising new applications, such as the utilization of phage enzymes in biotechnology
protocols, their applications to combat bacteria, or the specific proposed uses of phage
display to find molecules with high affinity for use as antibodies in medical applications.
Phage biology is in an exciting upswing that will lead to a better understanding of global
ecology and help us develop more tools from this new knowledge. The creation of the
plasmids described herein is one small step toward better understanding the inner
workings of phage proteins, and will allow us to have a better understanding and
improved utilization of these entities.
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